PARIS, June 4 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic company, today announces that Loic Maurel, M.D., will join ExonHit Therapeutics on July 1st as Chief Operating Officer. At the next meeting of the Supervisory Board, he will be appointed CEO (President du Directoire).
Laurent Condomine, Chairman of the Supervisory Board, commented: "We are delighted to have Loic Maurel joining ExonHit Therapeutics. His experience and track record in major as well as in biopharmaceutical companies, both in Europe and in North America, combined with his leadership qualities, will be of great value going into the future. Together with the newly formed Management Board, the ExonHit leadership team will focus on accelerating the Company's transformation from an R&D driven organization into a market and commercially driven company enabling ExonHit to meet its ultimate goal of providing therapeutic and diagnostic solutions in chronic diseases, in an effective and timely fashion."
Prior to joining ExonHit and since 2001, Loic Maurel served as
President and CEO of Debiovision Inc. in Canada, a Pharmaceutical
Development Company focusing on the development of innovative therapeutics
for unmet medical needs. During his tenure, he acquired clinical and
regulatory experience with FDA and EMEA exposures, filing an NDA in the
United States, Canada, France, and Switzerland. He also led several
licensing and acquisition activities in North America, Europe, and Asia.
From 1999 to 2001, Loic Maurel was Vice President Marketing and Specialty
Business of Novartis Canada. He successfully launched several products and
increased sales as a result of the restructuring of the Marketing and Sales
organization. Prior to this, he was Global Marketing Head for the
Cardiovascular, Metabolism and Respiratory Therapeutic Area at Novartis
Headquarters in Basel, Switzerland. He was responsible for the worldwide
launch of Diovan, the number one product of Novartis.
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved